🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Esther H. Zhou

United States Food and Drug Administration

ORCID: 0000-0003-4608-6850

Also affiliated with Center for Drug Evaluation and Research

Pharmacology, Toxicology and PharmaceuticsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Changes in emergency department visits for zolpidem‐attributed adverse drug reactions after FDA Drug Safety Communications”.

Changes in emergency department visits for zolpidem‐attributed adverse drug reactions after FDA Drug Safety Communications

Pharmacoepidemiology and Drug Safety(2020)10.1002/pds.4952

N/A

0DataRank · unranked

7 citations

Esther H. Zhou, Daniel S. Budnitz, Maribeth C. Lovegrove, Gerald J. Dal Pan, Andrew I. Geller

Trends in pediatric nonprescription analgesic/antipyretic exposures during the COVID-19 pandemic

Clinical Toxicology(2023)10.1080/15563650.2022.2158847

N/A

0DataRank · unranked

9 citations

Cooma Asonye, Ellen Pinnow, Valerie Pratt, Lynda McCulley, Nana Dwumfour +2 more

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020

Drug Safety(2024)10.1007/s40264-024-01443-3

N/A

0DataRank · unranked

6 citations

Ameet Sarpatwari, Krista F. Huybrechts, Joyce Lii, Su Been Lee, Gita A. Toyserkani +6 more